# A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota

> **NCT02833480** · PHASE2 · UNKNOWN · sponsor: **University of British Columbia** · enrollment: 69 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Fluticasone group
- **DRUG:** Budesonide group
- **DRUG:** Formoterol group

## Key facts

- **NCT ID:** NCT02833480
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2021-01
- **Final completion:** 2021-06
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2020-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833480, "A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02833480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*